ELVN
Enliven Therapeutics, Inc.
$33.63
-3.11%
$2.2B
No data for this timeframe.
Vol
Market Cap$2.2B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (94%)
Inst. Holders6 funds
Inst. Value$165.6M
Inst. Activity3 buys / 2 sells
Insider Activity0B / 9S
Insider Net $-$3.6M
Reddit Sentiment57° Neutral
SEC Reports1
Recent Activity
Jun 5, 2026
SEC
Board member Lori Anne Kunkel filed a Form 144 notice of intent to sell 20,000 shares of Enliven Therapeutics (ELVN), wi
144 — Impact 2/10
Jun 5, 2026
Insider
Kunkel Lori Anne sold 7,779 shares
Director @ $34.28 ($266.7K)
May 18, 2026
Insider
Collins Helen Louise sold 5,000 shares
CHIEF MEDICAL OFFICER @ $2.48 ($12.4K)
May 18, 2026
Insider
Collins Helen Louise sold 3,475 shares
CHIEF MEDICAL OFFICER @ $39.53 ($137.4K)
Inst.
MORGAN STANLEY — ADD
411,823 shares ($6.3M)
Inst.
WELLS FARGO & COMPANY/MN — ADD
43,056 shares ($663.1K)
Apr 16, 2026
short_volume
Short Volume: ELVN — 55.2% short (0.4M / 0.8M)
Short: 427,653 | Exempt: 0 | TRF Vol: 774,451 | Short Ratio: 55.2% | Off-exchange volume (dark pool
Price Targets
$59.22
+64.0% upside
Strong Buy
Current $36.11
Low $45.00
Median $59.00
High $80.00
9 analysts
$45.00
$80.00
Analyst Ratings
6Strong Buy
10Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 9, 2026 | Stifel | INITIATE | Buy |
| Jun 2, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
| May 8, 2026 | Goldman Sachs | MAINTAIN | Buy → Buy |
| Mar 26, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 25, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.37 ▲ +6.7% | $-0.43 — $-0.29 | 24% YoY | 3 |
| Next Q | $-0.44 ▲ +6.4% | $-0.48 — $-0.37 | -38% YoY | 3 |
| Current FY | $-1.75 ▲ +3.3% | $-1.98 — $-1.37 | 4% YoY | 4 |
| Next FY | $-2.43 ▼ -14.4% | $-2.90 — $-1.71 | -39% YoY | 4 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $109.5M | — |
| VANGUARD GROUP INC | $43.1M | — |
| MORGAN STANLEY | $6.3M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $5.5M | NEW |
| WELLS FARGO & COMPANY/MN | $663.1K | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 5, 2026 | Kunkel Lori | SELL | $266.7K |
| May 18, 2026 | Collins Helen | M | $12.4K |
| May 18, 2026 | Collins Helen | SELL | $137.4K |
| May 18, 2026 | Collins Helen | M | $0.00 |
| Apr 17, 2026 | Collins Helen | M | $12.4K |
Reddit Sentiment
57°
Neutral
Bearish
Neutral
Bullish
6 institutional holders with $165.6M total value (10,752,082 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, MORGAN. Net buying activity: 3 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 7,107,635 | $109.5M | 66.1% | — |
| 2 | VANGUARD GROUP INC | 2,801,665 | $43.1M | 26.1% | — |
| 3 | MORGAN STANLEY | 411,823 | $6.3M | 3.8% | ADD +59.4% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 355,192 | $5.5M | 3.3% | NEW |
| 5 | WELLS FARGO & COMPANY/MN | 43,056 | $663.1K | 0.4% | ADD +66.7% |
| 6 | BANK OF AMERICA CORP /DE/ | 32,711 | $503.7K | 0.3% | ADD +38.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 258,384 | 411,823 | +59.4% | $6.3M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 25,824 | 43,056 | +66.7% | $663.1K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 23,543 | 32,711 | +38.9% | $503.7K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 59,000 | 0 | -100.0% | $0.00 | 2025-Q4 |
| Duquesne Family Office LLC | EXIT | 947,405 | 0 | -100.0% | $0.00 | 2025-Q4 |
| UBS Group AG | TRIM | 138,280 | 79,508 | -42.5% | $1.6M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 23,900 | 59,000 | +146.9% | $1.2M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 16,656 | 25,824 | +55.0% | $528.6K | 2025-Q3 |
| Duquesne Family Office LLC | DOUBLED | 463,000 | 947,405 | +104.6% | $19.4K | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 81,315 | 254,848 | +213.4% | $5.1M | 2025-Q2 |
| UBS Group AG | ADD | 70,436 | 138,280 | +96.3% | $2.8M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 11,900 | 23,900 | +100.8% | $479.4K | 2025-Q2 |
| CITADEL ADVISORS LLC | TRIM | 1,739,932 | 1,124,238 | -35.4% | $22.1M | 2025-Q1 |
| MORGAN STANLEY | TRIM | 110,606 | 81,315 | -26.5% | $1.6M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 11,900 | — | $234.2K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 14,620 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 27,682 | 87,188 | +215.0% | $2.0M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 11,118 | 16,666 | +49.9% | $375.0K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 255,277 | — | $6.5M | 2024-Q3 |
| MORGAN STANLEY | ADD | 68,300 | 135,407 | +98.3% | $3.5M | 2024-Q3 |
11 unique insiders with 9 transactions. Net insider value: -$3.6M ($0.00 bought, $3.6M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | Kunkel Lori Anne | Director | SELL | 7,779 | $34.28 | $266.7K |
| May 18, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | M | 5,000 | $2.48 | $12.4K |
| May 18, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | SELL | 3,475 | $39.53 | $137.4K |
| May 18, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | M | 5,000 | $0.00 | $0.00 |
| Apr 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | M | 5,000 | $2.48 | $12.4K |
| Apr 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | SELL | 140 | $45.81 | $6.4K |
| Apr 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | M | 5,000 | $0.00 | $0.00 |
| Mar 25, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | M | 40,000 | $2.48 | $99.2K |
| Mar 25, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | SELL | 40,000 | $35.10 | $1.4M |
| Mar 25, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | M | 40,000 | $0.00 | $0.00 |
| Mar 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | M | 5,000 | $2.48 | $12.4K |
| Mar 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | SELL | 5,000 | $27.76 | $138.8K |
| Mar 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | M | 5,000 | $0.00 | $0.00 |
| Mar 10, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | M | 10,129 | $2.48 | $25.1K |
| Mar 10, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | SELL | 10,129 | $30.19 | $305.8K |
| Mar 10, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | M | 10,129 | $0.00 | $0.00 |
| Mar 9, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | M | 29,871 | $2.48 | $74.1K |
| Mar 9, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | SELL | 29,871 | $30.02 | $896.8K |
| Mar 9, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | M | 29,871 | $0.00 | $0.00 |
| Mar 6, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | SELL | 10,000 | $29.58 | $295.8K |
| Feb 12, 2026 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | A | 18,750 | $0.00 | $0.00 |
| Feb 12, 2026 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | A | 112,500 | $0.00 | $0.00 |
| Feb 12, 2026 | Gupta Rishi | Director | A | 33,989 | $0.00 | $0.00 |
| Feb 12, 2026 | Garland J. Scott | Director | A | 1,427 | $0.00 | $0.00 |
| Feb 12, 2026 | Derynck Mika K | Director | A | 17,126 | $0.00 | $0.00 |
| Feb 12, 2026 | Bauer Jake | Director | A | 17,126 | $0.00 | $0.00 |
| Feb 12, 2026 | Ballal Rahul D. | Director | A | 17,126 | $0.00 | $0.00 |
| Feb 12, 2026 | Heyman Richard A. | Director | A | 19,234 | $0.00 | $0.00 |
| Feb 12, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | A | 25,000 | $0.00 | $0.00 |
| Feb 12, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | A | 150,000 | $0.00 | $0.00 |
| Feb 12, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | A | 25,000 | $0.00 | $0.00 |
| Feb 12, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | A | 150,000 | $0.00 | $0.00 |
| Feb 12, 2026 | Kunkel Lori Anne | Director | A | 17,126 | $0.00 | $0.00 |
| Feb 12, 2026 | Patel Anish | CHIEF OPERATING OFFICER | A | 20,000 | $0.00 | $0.00 |
| Feb 12, 2026 | Patel Anish | CHIEF OPERATING OFFICER | A | 120,000 | $0.00 | $0.00 |
| Feb 6, 2026 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | SELL | 5,000 | $29.04 | $145.2K |
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 2.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (94% buy). Based on 17 analysts: 6 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$59.22 mean target
+64.0% upside
Strong Buy (1.00)
$45.00 Low
$80.00 High
| Metric | Value |
|---|---|
| Current Price | $36.11 |
| Target Low | $45.00 |
| Target Mean | $59.22 |
| Target Median | $59.00 |
| Target High | $80.00 |
| # Analysts | 9 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.37 | $-0.43 | $-0.29 | 23.8% | +6.7% | 1↑ 0↓ | $0.0B | 0.0% | 3 |
| Next Q 2026-09-30 |
$-0.44 | $-0.48 | $-0.37 | -37.5% | +6.4% | 1↑ 0↓ | $0.0B | 0.0% | 3 |
| Current FY 2026-12-31 |
$-1.75 | $-1.98 | $-1.37 | 4.4% | +3.3% | 1↑ 0↓ | $0.0B | 0.0% | 4 |
| Next FY 2027-12-31 |
$-2.43 | $-2.90 | $-1.71 | -38.9% | -14.4% | 1↑ 0↓ | $0.0B | 0.0% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.373 | |
| 7d ago | $-0.400 | +0.027 |
| 30d ago | $-0.400 | +0.027 |
| 60d ago | $-0.420 | +0.047 |
| 90d ago | $-0.560 | +0.187 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 9, 2026 | Stifel | INITIATE | — | Buy |
| Jun 2, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| May 8, 2026 | Goldman Sachs | MAINTAIN | Buy | Buy |
| Mar 26, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 25, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 10 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 5 | 10 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 5 | 10 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 5 | 10 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 5 | 10 | 1 | 0 | 0 | 94% | |
| Jan 1, 2026 | 5 | 10 | 1 | 0 | 0 | 94% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
57°
Neutral
Bearish
Neutral
Bullish
3 mentions
1 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 28, 2026 | 2 | 58° Warm | 1 | 0 | 2 |
| Mar 28, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Apr 16, 2026
short_volume
Short Volume: ELVN — 55.2% short (0.4M / 0.8M)
Short: 427,653 | Exempt: 0 | TRF Vol: 774,451 | Short Ratio: 55.2% | Off-exchange volume (dark pool + OTC)
Apr 6, 2026
short_interest
FTD: ELVN — 15,603 shares ($0.6M) failed to deliver
Settlement: 20260406, Price: $38.83, FTD Value: $605,864.49, ENLIVEN THERAPEUTICS INC COM
Apr 2, 2026
short_interest
FTD: ELVN — 15,707 shares ($0.6M) failed to deliver
Settlement: 20260402, Price: $37.79, FTD Value: $593,567.53, ENLIVEN THERAPEUTICS INC COM
Mar 12, 2026
earnings_calendar
ELVN Q4 2025 Earnings After Market Close — 2026-03-12
Mar 11, 2026
earnings_calendar
ELVN Q4 2025 Earnings After Market Close — 2026-03-11
Mar 5, 2026
short_interest
FTD: ELVN — 23,773 shares ($0.7M) failed to deliver
Settlement: 20260305, Price: $29.98, FTD Value: $712,714.54, ENLIVEN THERAPEUTICS INC COM
Mar 4, 2026
short_interest
FTD: ELVN — 30,016 shares ($0.9M) failed to deliver
Settlement: 20260304, Price: $28.75, FTD Value: $862,960, ENLIVEN THERAPEUTICS INC COM
Mar 3, 2026
short_interest
FTD: ELVN — 23,981 shares ($0.7M) failed to deliver
Settlement: 20260303, Price: $29.50, FTD Value: $707,439.5, ENLIVEN THERAPEUTICS INC COM
Feb 20, 2026
short_interest
FTD: ELVN — 28,794 shares ($0.8M) failed to deliver
Settlement: 20260220, Price: $26.16, FTD Value: $753,251.04, ENLIVEN THERAPEUTICS INC COM
Feb 18, 2026
short_interest
FTD: ELVN — 59,914 shares ($1.6M) failed to deliver
Settlement: 20260218, Price: $26.13, FTD Value: $1,565,552.82, ENLIVEN THERAPEUTICS INC COM